Amgen (AMGN-NASDAQ) posted EPS of $0.90, but $0.71 on GAAP EPS. Revenues were $3.73 Billion versus $3.7 Billion estimates. Revenues are projected for $15.4 to $16 Billion for 2007 and adjusted EPS put for 2007 at $4.30 to $4.50. Estimates for the quarter were $0.94 to $0.95 depending on your consensus, but 2007 estimates are $4.43.
The stock closed down 0.4% at $74.85 and is down almost 2% around $73.50 in the initial reaction. At the mid-point this is only a 17 P/E for 2007, so investors aren’t willing to pay up for Amgen’s earnings based on Congressional scares and potential patent issues in 2008 and beyond. The valuation isn’t the issue here, because this ons has been cheaper than many Big Pharma stocks for a while. Its market cap is $87 Billion.
Amgen is no longer treated like a biotech, it’s treated like a plain Jane drug stock. That might not be fair, but the market sets the rules.
Jon C. Ogg
January 25, 2007
Get Ready To Retire (Sponsored)
Start by taking a quick retirement quiz from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes, or less.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Get started right here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
